A history of heart failure predicts arrhythmia treatment efficacy: Data from the Antiarrythmics versus Implantable Defibrillators (AVID) Study

Michael A. Brodsky, John McAnulty, Douglas P. Zipes, Christina Baessler, Alfred P. Hallstrom

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: In survivors of life-threatening ventricular tachycardia (VT), a history of CHF (HxCHF) before the VT episode may provide different prognostic information than their measured left ventricular ejection fraction (LVEF). Methods: We evaluated outcomes from patients in the AVID study. Patients were included in the study if they presented with ventricular fibrillation, VT with syncope or VT with hemodynamic compromise, and LVEF ≤40%. Treatment options included implantable cardioverter defibrillator (ICD) or antiarrhythmic drugs (AAD), usually amiodarone. Results: As expected, a HxCHF is associated with an increased and high risk of arrhythmic and nonarrhythmic death. However, an interaction was observed between arrhythmia treatment (ICD or AAD) and HxCHF status: the survival advantage with an ICD, as compared with AAD therapy, is largely restricted to HxCHF patients. Conclusions: The ICD is no better than AAD therapy in preventing arrhythmic death in patients with no HxCHF. In this data set, a HxCHF is somewhat more accurate in predicting prognosis and the response to therapy than a reduced LVEF.

Original languageEnglish
Pages (from-to)724-730
Number of pages7
JournalAmerican Heart Journal
Volume152
Issue number4
DOIs
StatePublished - Oct 2006

Fingerprint

Implantable Defibrillators
Anti-Arrhythmia Agents
Cardiac Arrhythmias
Ventricular Tachycardia
Heart Failure
Stroke Volume
Drug Therapy
Amiodarone
Syncope
Ventricular Fibrillation
Survivors
Therapeutics
Hemodynamics
Survival

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

A history of heart failure predicts arrhythmia treatment efficacy : Data from the Antiarrythmics versus Implantable Defibrillators (AVID) Study. / Brodsky, Michael A.; McAnulty, John; Zipes, Douglas P.; Baessler, Christina; Hallstrom, Alfred P.

In: American Heart Journal, Vol. 152, No. 4, 10.2006, p. 724-730.

Research output: Contribution to journalArticle

Brodsky, Michael A. ; McAnulty, John ; Zipes, Douglas P. ; Baessler, Christina ; Hallstrom, Alfred P. / A history of heart failure predicts arrhythmia treatment efficacy : Data from the Antiarrythmics versus Implantable Defibrillators (AVID) Study. In: American Heart Journal. 2006 ; Vol. 152, No. 4. pp. 724-730.
@article{28dbdad6d0a6425b9fd417d38a9554fb,
title = "A history of heart failure predicts arrhythmia treatment efficacy: Data from the Antiarrythmics versus Implantable Defibrillators (AVID) Study",
abstract = "Background: In survivors of life-threatening ventricular tachycardia (VT), a history of CHF (HxCHF) before the VT episode may provide different prognostic information than their measured left ventricular ejection fraction (LVEF). Methods: We evaluated outcomes from patients in the AVID study. Patients were included in the study if they presented with ventricular fibrillation, VT with syncope or VT with hemodynamic compromise, and LVEF ≤40{\%}. Treatment options included implantable cardioverter defibrillator (ICD) or antiarrhythmic drugs (AAD), usually amiodarone. Results: As expected, a HxCHF is associated with an increased and high risk of arrhythmic and nonarrhythmic death. However, an interaction was observed between arrhythmia treatment (ICD or AAD) and HxCHF status: the survival advantage with an ICD, as compared with AAD therapy, is largely restricted to HxCHF patients. Conclusions: The ICD is no better than AAD therapy in preventing arrhythmic death in patients with no HxCHF. In this data set, a HxCHF is somewhat more accurate in predicting prognosis and the response to therapy than a reduced LVEF.",
author = "Brodsky, {Michael A.} and John McAnulty and Zipes, {Douglas P.} and Christina Baessler and Hallstrom, {Alfred P.}",
year = "2006",
month = "10",
doi = "10.1016/j.ahj.2006.04.021",
language = "English",
volume = "152",
pages = "724--730",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - A history of heart failure predicts arrhythmia treatment efficacy

T2 - Data from the Antiarrythmics versus Implantable Defibrillators (AVID) Study

AU - Brodsky, Michael A.

AU - McAnulty, John

AU - Zipes, Douglas P.

AU - Baessler, Christina

AU - Hallstrom, Alfred P.

PY - 2006/10

Y1 - 2006/10

N2 - Background: In survivors of life-threatening ventricular tachycardia (VT), a history of CHF (HxCHF) before the VT episode may provide different prognostic information than their measured left ventricular ejection fraction (LVEF). Methods: We evaluated outcomes from patients in the AVID study. Patients were included in the study if they presented with ventricular fibrillation, VT with syncope or VT with hemodynamic compromise, and LVEF ≤40%. Treatment options included implantable cardioverter defibrillator (ICD) or antiarrhythmic drugs (AAD), usually amiodarone. Results: As expected, a HxCHF is associated with an increased and high risk of arrhythmic and nonarrhythmic death. However, an interaction was observed between arrhythmia treatment (ICD or AAD) and HxCHF status: the survival advantage with an ICD, as compared with AAD therapy, is largely restricted to HxCHF patients. Conclusions: The ICD is no better than AAD therapy in preventing arrhythmic death in patients with no HxCHF. In this data set, a HxCHF is somewhat more accurate in predicting prognosis and the response to therapy than a reduced LVEF.

AB - Background: In survivors of life-threatening ventricular tachycardia (VT), a history of CHF (HxCHF) before the VT episode may provide different prognostic information than their measured left ventricular ejection fraction (LVEF). Methods: We evaluated outcomes from patients in the AVID study. Patients were included in the study if they presented with ventricular fibrillation, VT with syncope or VT with hemodynamic compromise, and LVEF ≤40%. Treatment options included implantable cardioverter defibrillator (ICD) or antiarrhythmic drugs (AAD), usually amiodarone. Results: As expected, a HxCHF is associated with an increased and high risk of arrhythmic and nonarrhythmic death. However, an interaction was observed between arrhythmia treatment (ICD or AAD) and HxCHF status: the survival advantage with an ICD, as compared with AAD therapy, is largely restricted to HxCHF patients. Conclusions: The ICD is no better than AAD therapy in preventing arrhythmic death in patients with no HxCHF. In this data set, a HxCHF is somewhat more accurate in predicting prognosis and the response to therapy than a reduced LVEF.

UR - http://www.scopus.com/inward/record.url?scp=33748678713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748678713&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2006.04.021

DO - 10.1016/j.ahj.2006.04.021

M3 - Article

C2 - 16996848

AN - SCOPUS:33748678713

VL - 152

SP - 724

EP - 730

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 4

ER -